RESUMEN
We report the synthesis of a novel heteroheptanuclear metal string complex (HMSC) [Ni3Ru2Ni2(µ7-teptra)4(NCS)2](PF6) 1 supported by tetra-pyridyl-tri-amine (H3teptra) ligands. We employed X-ray diffraction and other spectroscopic techniques to characterize the complex. The observed remarkably short Ru-Ru distance of 2.2499(3) Å for 1 is indicative of a unique metal-metal interaction in the mixed-valence [Ru2]5+ (S = 3/2) unit. The complex exhibits a relatively high magnetic moment value of 4.55 B.M. at 4 K, which increases rapidly to 6.00 B.M. at 30 K and remains at 6.11 B.M. from 50 to 300 K as shown by SQUID measurements, indicating a high spin (S≥ 3/2) system which is further supported by the analyses of EPR spectra at low temperatures. These magnetic behaviors can be ascribed to the result of spin-exchange interactions among multi-spin centers.
RESUMEN
AIM: To construct and express an anti-VEGFR2/anti-CD3 bispecific single-chain antibody (bscVEGFR2×CD3)and to identify its binding specificities to CD3 and VEGFR2. METHODS: The gene encoding anti-VEGFR2/anti-CD3 bispecific single-chain antibody was designed and synthesized. Bispecific single-chain antibody (bsc-Ab) DNA was subcloned into a eukaryotic expression vector pcDNA3.1(+), then transfected into Chinese hamster ovary (CHO) cells and stable expression cell lines were selected. Expressed Bsc-Ab was purified by His-tag affinity chromatography and confirmed by 120 g/L SDS-PAGE and Western blotting. Antigen binding activity of the bsc-Ab was analyzed by FACS. RESULTS: The plasmid DNA containing bispecific single-chain fragments were confirmed. BscVEGFR2×CD3 was secreted by CHO into the supernatant. Six stable expression cell lines were established. The molecular weight of bsc-Ab was correct indicated by SDS-PAGE and Western blotting. The bsc-Ab could specifically bind to CD3(+); jurkat cells and VEGFR2(+); A375 cells. CONCLUSION: An anti-VEGFR2/anti-CD3 bispecific single-chain antibody is successfully constructed and expressed, and the antibody has specific binding capacity to CD3 and VEGFR2.